Although specific VCAM1 inhibitors are not available, probucol—a lipid lowering drug with pleiotropic effects including VCAM1 inhibition—was tested for secondary prevention against atherosclerotic events in patients with CAD (PROSPECTIVE, UMIN000003307)47. Here, VCAM1 is linked to coronary artery disorder.